Partnerships are always vital to our industry to help bring new therapies to patients, but they are watched especially closely when economic downturns close the IPO window. E&Y reported that while the biotech IPO market fell 93% from 2021, partnerships rose to a projected value of $132.1 billion in 2022, the third-highest total in the past decade. This diverse panel of experts will discuss the differences and similarities in best practices for partnerships both in the best of times, and in the worst of times. This will include reviewing the current landscape, exchanging advice, and discussing any changes to be ready for when the economy is on the rise again.